24/7 Market News- Alzamend Neuro to Perform Phase II Clinical Trial of AL001 with Mass General

August 19, 2024

DENVER, Colo., Aug 19, 2024 (247marketnews.com)- Alzamend Neuro (Nasdaq: ALZN) stated that it Massachusetts General Hospital will be its contract research organization to conduct its Phase II clinical study of AL001 for treatment of patients with PTSD.

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the study’s principal investigator at Massachusetts General Hospital, which is Harvard’s original clinical education and research facility, and center of the world’s largest hospital-based research program.

Alzamend’s CEO, Stephan Jackman, stated, “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001.

“If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require TDM, it would constitute a major improvement over current lithium-based treatments and positively impact the 9+ million Americans afflicted with PTSD. We look forward to providing more details regarding the study’s timeline and market opportunity in the near future.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (ALZN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.